Biohaven Ltd. (BHVN) announced positive results from a pivotal study demonstrating the efficacy of troriluzole in slowing the progression of Spinocerebellar Ataxia (SCA). The drug showed statistically significant improvements in f-SARA scores after three years, leading to a potential FDA approval and commercialization in 2025.